Stay updated on SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.

Latest updates to the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA new version of the clinical trial record was added, documenting updates to its recruitment and study status.SummaryDifference0.0%

- Check15 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.0%

- Check22 days agoChange DetectedA banner announces NIH website transition updates and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference0.3%

- Check29 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2.SummaryDifference0.0%

- Check36 days agoChange DetectedThe ClinicalTrials.gov footer now identifies the site as revision v3.7.1 instead of v3.7.0.SummaryDifference0.0%

- Check57 days agoChange DetectedThe history now shows a new revision entry labeled v3.7.0. The previous entry v3.6.6 has been removed.SummaryDifference0.0%

Stay in the know with updates to SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.